Ranibizumab Lucentis®
The SHIKARI® Ranibizumab portfolio provides a quantitative free-drug assay for human serum or plasma.
Why Ranibizumab is relevant to biological-drug monitoring research
Ranibizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Ranibizumab is a humanised monoclonal-antibody Fab fragment that binds VEGF-A and inhibits VEGF-driven neovascularisation and vascular permeability. Source ↗
Approved Indications
EMA-authorised ophthalmic uses include neovascular age-related macular degeneration and several causes of retinal macular oedema or choroidal neovascularisation in defined populations. EMA source ↗
Systemic Exposure After Intravitreal Dosing
Serum exposure after intravitreal dosing is extremely low and should not be interpreted as an ocular therapeutic target:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
One verified Ranibizumab research assay
Ligand-binding ELISA for quantitative analysis of free ranibizumab in human serum or plasma.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-RAN | RAN-FD-LUC | Quantitative | Free ranibizumab | Human serum / plasma | 10 µL | 70 min | LOD 0.625; LOQ 1 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Publications Using SHIKARI® Ranibizumab Kits 1
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Planning a Ranibizumab research study?
Matrix Biotek can help identify the appropriate Ranibizumab assay and prepare regional quotation and delivery information.